Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00672191 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
A Phase 2 study of HIV Infections, sponsored by Argos Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 12
- Study locations
NCT00672191 is a Phase 2 study of HIV Infections that has completed, run by Argos Therapeutics. The registered enrollment target is 59 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 5 states.
The verdict
NCT00672191, a Phase 2 study of HIV Infections, has completed, sponsored by Argos Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.
Conditions Studied
Interventions
- BIOLOGICAL AGS-004
Study Locations (12)
Ontario
- Hamilton Health Sciences - McMaster University Medical Centre - Hamilton
- The Ottawa Hospital - Ottawa
- Sunnybrook Health Sciences Center - Toronto
- Maple Leaf Clinic - Toronto
- UHN - Toronto
Quebec
- Clinique medicale l'Actuel - Montreal
- Clinique Medical du Quartier Latin - Montreal
- Montreal Chest Institute - Montreal
- CHUM - Montreal
Pennsylvania
- Practice Comprehensive Care Practice Div of Onfectious Disease & HIV Med - Philadelphia
Alberta
- Southern Alberta Clinic - Calgary
British Columbia
- Providence Health Care Society / The University of British Columbia / BC Centre for Excellence in HIV/AIDS - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00672191
The ClinicalTrials.gov registry entry for NCT00672191 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is Argos Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which AGS-004 is the first listed.
NCT00672191 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Ontario, Quebec, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00672191 about?
NCT00672191 is a clinical study titled "Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV". The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping a...
What is the current status of trial NCT00672191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2008-02. Estimated completion is 2011-11.
What conditions does trial NCT00672191 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00672191?
The interventions under investigation include: AGS-004 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00672191?
This trial is sponsored by Argos Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00672191 being conducted?
This trial has 12 study locations across Pennsylvania, Alberta, British Columbia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.